Skip to content

Efficacy and safety of gamma knife radiosurgery for asymptomatic intracranial hemangioblastoma in patients with von Hippel-Lindau disease: A prospective interventional trial

Efficacy and safety of gamma knife radiosurgery for asymptomatic intracranial hemangioblastoma in patients with von Hippel-Lindau disease: A prospective interventional trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1032220685
Enrollment
20
Registered
2023-03-03
Start date
2023-12-11
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asymptomatic intracranial hemangioblastoma in patients with von Hippel-Lindau disease asymptomatic intracranial hemangioblastoma

Interventions

Gamma Knife radiosurgery for asymptomatic intracranial hemangioblastomas in Von Hippel-Lindau disease

Sponsors

Umekawa Motoyuki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) With a diagnosis of Von Hippel-Lindau (VHL) disease based on clinical criteria of the VHL guideline (2017 edition) (2) With intracranial hemangioblastomas detected by contrast-enhanced MRI without neurological symptoms (3) Aged from 18 to 80 years at the time of informed consent is taken (4) Male or female (5) Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation (6) Able to attend all scheduled visits

Exclusion criteria

Exclusion criteria: (1) With signs of cerebellar compression, requiring surgery (2) With neurological symptoms (3) With a large tumor, the maximum diameter of the tumor parenchyma of more than 25 mm (4) With a large cystic tumor, the maximum diameter including cystic part of more than 30 mm (5) Having chemotherapy for tumors except brain tumors (6) Karnofsky Performance Score of less than 70 (7) With uncontrolled malignancy (8) With severe liver failure or renal failure (9) Unable to have MRI scans (10) With severe abnormality in usual vital signs: systolic blood pressure of 200mmHg or more, diastolic blood pressure of 120 mmHg or more, SpO2 in room air of less than 90%, pulse rate of 120 bpm or more (11) Judged as ineligible by clinical investigators

Design outcomes

Primary

MeasureTime frame
Local control rate at 5 years

Secondary

MeasureTime frame
(1) Intervention-free survival (2) Disease specific survival at 5 years (3) Rate of peritumoral edema after treatment every 6 months (4) Neurological outcome at 5 years

Contacts

Public ContactMotoyuki Umekawa

The University of Tokyo Hospital

moto.umekawa@gmail.com+81-3-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026